{
    "Clinical Trial ID": "NCT00304096",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Stratum 1: Received Hormonal Therapy",
        "  Participants received hormonal therapy",
        "INTERVENTION 2: ",
        "  Stratum 2: Had Not Received Hormonal Therapy",
        "  Participants had not received hormonal therapy"
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Histologically or cytologically confirmed adenocarcinoma of the breast",
        "  Stage III or IV disease",
        "  Primary or recurrent disease",
        "  Invasive lobular carcinoma allowed",
        "  HLA-A1, -A2, -A3, or -A31 positive",
        "  Underwent and recovered from prior primary therapy",
        "  Patients with no clinical or radiological evidence of disease who had a previous diagnosis of stage III or IV breast cancer must have undergone prior antineoplastic therapy including, but not limited to, surgery, chemotherapy, and radiotherapy within the past 36 months",
        "  Must have at least one undissected axillary and/or inguinal lymph node basin",
        "  No history of brain metastases",
        "  Hormone receptor status",
        "  Estrogen receptor-positive or -negative tumor",
        "  PATIENT CHARACTERISTICS:",
        "  ECOG performance status of 0 or 1",
        "  Body weight > 110 lbs (without clothes)",
        "  Male or female",
        "  Menopausal status not specified",
        "  Absolute neutrophil count > 1000/mm^3",
        "  Platelet count > 100,000/mm^3",
        "  Hemoglobin > 9 g/dL",
        "  Hemoglobin A1c < 7%",
        "  AST and ALT  2.5 x upper limit of normal (ULN)",
        "  Bilirubin  2.5 x ULN",
        "  Alkaline phosphatase  2.5 x ULN",
        "  Creatinine  1.5 x ULN",
        "  HIV negative",
        "  Hepatitis C negative",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective contraception",
        "  No known or suspected allergies to any component of the vaccine",
        "  No active infection requiring antibiotics",
        "  No New York Heart Association class III or IV heart disease",
        "  No autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement, except the following:",
        "  Laboratory evidence of autoimmune disease (e.g., positive ANA titer) without symptoms",
        "  Clinical evidence of vitiligo",
        "  Other forms of depigmenting illness",
        "  Mild arthritis requiring nonsteroidal antiinflammatory drugs",
        "  No medical contraindication or potential problem that would preclude study participation",
        "  PRIOR CONCURRENT THERAPY:",
        "  More than 4 weeks since prior surgery",
        "  More than 4 weeks since prior and no concurrent chemotherapy and radiotherapy",
        "  More than 4 weeks since prior and no concurrent allergy desensitization injections",
        "  More than 4 weeks since prior parenteral, oral, or inhaled corticosteroids",
        "  No concurrent inhaled steroids (e.g., Advair\u00ae or triamcinolone acetonide)",
        "  Prior or concurrent topical corticosteroids allowed",
        "  More than 4 weeks since prior and no concurrent growth factors (e.g., epoetin alfa, darbepoetin alfa, or pegfilgrastim)",
        "  More than 4 weeks since prior and no concurrent other investigational medication",
        "  More than 4 weeks since prior and no concurrent other agents with putative immunomodulating activity except for non-steroidal anti-inflammatory agents",
        "  Prior and concurrent hormonal therapy (e.g., tamoxifen, raloxifene, toremifene, fulvestrant, letrozole, anastrozole, or exemestane) allowed",
        "  No prior vaccination with any synthetic peptides in this protocol",
        "  Vaccines for infectious disease (e.g., influenza) allowed, provided they are administered  2 weeks prior to or  2 weeks after study vaccine",
        "  Short term therapy for acute conditions not related to breast cancer allowed",
        "  No concurrent illegal drugs"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  The Number of Participants Who Experienced Dose-limiting Adverse Events",
        "  Safety of the 9-peptide mixture if fewer than 33% of patients experience a dose-limiting toxicity",
        "  Time frame: 30 days post administration of last vaccine",
        "Results 1: ",
        "  Arm/Group Title: Stratum 1: Received Hormonal Therapy",
        "  Arm/Group Description: Participants received hormonal therapy",
        "  Overall Number of Participants Analyzed: 6",
        "  Measure Type: Number",
        "  Unit of Measure: participants  1",
        "Results 2: ",
        "  Arm/Group Title: Stratum 2: Had Not Received Hormonal Therapy",
        "  Arm/Group Description: Participants had not received hormonal therapy",
        "  Overall Number of Participants Analyzed: 5",
        "  Measure Type: Number",
        "  Unit of Measure: participants  0"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/6 (16.67%)",
        "  Fever  [1]1/6 (16.67%)",
        "Adverse Events 2:",
        "  Total: 0/5 (0.00%)",
        "  Fever  [1]0/5 (0.00%)"
    ]
}